Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma (vol 80, pg 1455, 2020)

被引：0
|
作者：
Lamb, Yvette N. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2021年 / 81卷 / 01期
关键词：
D O I：
10.1007/s40265-020-01455-0
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Correction in reviewer name.
引用
收藏
页码：183 / 183
页数：1
相关论文
共 50 条
  • [1] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Yvette N. Lamb
    [J]. Drugs, 2020, 80 : 1455 - 1464
  • [2] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Lamb, Yvette N.
    [J]. DRUGS, 2020, 80 (14) : 1455 - 1464
  • [3] Correction to: Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Yvette N. Lamb
    [J]. Drugs, 2021, 81 : 183 - 183
  • [4] Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
    Moreau, Philippe
    Giralt, Sergio A.
    [J]. LEUKEMIA RESEARCH, 2012, 36 : S13 - S18
  • [5] Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
    Callander, Natalie S.
    Silbermann, Rebecca
    Kaufman, Jonathan L.
    Godby, Kelly N.
    Laubach, Jacob
    Schmidt, Timothy M.
    Sborov, Douglas W.
    Medvedova, Eva
    Reeves, Brandi
    Dhakal, Binod
    Rodriguez, Cesar
    Chhabra, Saurabh
    Chari, Ajai
    Bal, Susan
    Anderson, Larry D.
    Dholaria, Bhagirathbhai R.
    Nathwani, Nitya
    Hari, Parameswaran
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Giri, Smith
    Costa, Luciano J.
    Usmani, Saad Z.
    Richardson, Paul G.
    Voorhees, Peter M.
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [6] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    [J]. BLOOD, 2020, 136 (08) : 936 - 945
  • [7] Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
    Shaji Kumar
    [J]. Current Hematologic Malignancy Reports, 2011, 6 : 104 - 112
  • [8] Treatment of transplant-eligible patients with newly diagnosed multiple myeloma
    Nakaseko, Chiaki
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
    Kumar, Shaji
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 104 - 112
  • [10] Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    Syed, Yahiya Y.
    [J]. DRUGS, 2019, 79 (04) : 447 - 454
12345